MedPage Today

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST

Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed.
Medical Xpress

Imatinib shows improved outcomes for patients with severe COVID-19 in the CounterCOVID clinical trial

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated ...
ascopubs.org

Oncologic equivalence of brand-name vs generic imatinib in neoadjuvant KIT exon 11 GIST: A real-world international cohort study.

Standard-dose ripretinib plus sunitinib versus ripretinib dose escalation in advanced GIST after progression on four prior therapies: Preliminary results of a multicenter cohort study. Tumor size ...
News Medical

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated ...
Business Wire

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary ...